Validation of a novel framework defining the acceptable standard of care for heart failure with reduced ejection fraction

Validation of a novel framework defining the acceptable standard of care for heart failure with reduced ejection fraction

Abstract Background In heart failure with reduced ejection fraction (HFrEF), uptitration of neurohormonal antagonists to trial-proven doses shown to reduce mortality is challenging and seldomly achieved in clinical practice. A major reason for underdosing of these agents is the lack of a clear descr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European heart journal 2021-10, Vol.42 (Supplement_1)
Hauptverfasser: Lopes, P, Albuquerque, F, Freitas, P, Presume, J, Rocha, B, Cunha, G, Strong, C, Tralhao, A, Trabulo, M, Ferreira, J, Ventosa, A, Aguiar, C, Mendes, M, Ferreira, A
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_1
container_start_page
container_title European heart journal
container_volume 42
creator Lopes, P
Albuquerque, F
Freitas, P
Presume, J
Rocha, B
Cunha, G
Strong, C
Tralhao, A
Trabulo, M
Ferreira, J
Ventosa, A
Aguiar, C
Mendes, M
Ferreira, A
description Abstract Background In heart failure with reduced ejection fraction (HFrEF), uptitration of neurohormonal antagonists to trial-proven doses shown to reduce mortality is challenging and seldomly achieved in clinical practice. A major reason for underdosing of these agents is the lack of a clear description of what constitutes an acceptable standard of care in HFrEF. To address this limitation, a novel framework for describing the physician adherence to evidence-based treatment was recently proposed. The aim of our study was to evaluate and validate the proposed framework in a real-world population of patients with HFrEF. Methods A cohort of patients with HFrEF, defined as left ventricular ejection fraction (LVEF)
doi_str_mv 10.1093/eurheartj/ehab724.0914
format Article
fullrecord <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_eurheartj_ehab724_0914</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/eurheartj/ehab724.0914</oup_id><sourcerecordid>10.1093/eurheartj/ehab724.0914</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1374-5a8f372d64fd1516429469274aa50f678bf444b4c006edcd81c0219ef630e0303</originalsourceid><addsrcrecordid>eNqNkMtOwzAQRS0EEqXwC8g_kHbsOE68RBUvqRIbQOyiiT0mLmlSOQlV_562VKxZzdVI587oMHYrYCbApHMaY00Yh9WcaqxyqWZghDpjE5FJmRitsnM2AWGyROvi45Jd9f0KAAot9ITt3rEJDofQtbzzHHnbfVPDfcQ1bbv4xR350Ib2kw81cbSWNgNWDfF-wNZhdAfKYiTuu8iPf3CPoRn3m20Yah7JjZYcpxXZ45V99TFcswuPTU83pzllbw_3r4unZPny-Ly4WyZWpLlKMix8mkunlXciE1pJo7SRuULMwOu8qLxSqlIWQJOzrhAWpDDkdQoEKaRTpn97bez6PpIvNzGsMe5KAeVBYPknsDwJLA8C96D4Bbtx81_mB9QHeug</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Validation of a novel framework defining the acceptable standard of care for heart failure with reduced ejection fraction</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Lopes, P ; Albuquerque, F ; Freitas, P ; Presume, J ; Rocha, B ; Cunha, G ; Strong, C ; Tralhao, A ; Trabulo, M ; Ferreira, J ; Ventosa, A ; Aguiar, C ; Mendes, M ; Ferreira, A</creator><creatorcontrib>Lopes, P ; Albuquerque, F ; Freitas, P ; Presume, J ; Rocha, B ; Cunha, G ; Strong, C ; Tralhao, A ; Trabulo, M ; Ferreira, J ; Ventosa, A ; Aguiar, C ; Mendes, M ; Ferreira, A</creatorcontrib><description>Abstract Background In heart failure with reduced ejection fraction (HFrEF), uptitration of neurohormonal antagonists to trial-proven doses shown to reduce mortality is challenging and seldomly achieved in clinical practice. A major reason for underdosing of these agents is the lack of a clear description of what constitutes an acceptable standard of care in HFrEF. To address this limitation, a novel framework for describing the physician adherence to evidence-based treatment was recently proposed. The aim of our study was to evaluate and validate the proposed framework in a real-world population of patients with HFrEF. Methods A cohort of patients with HFrEF, defined as left ventricular ejection fraction (LVEF) &lt;40%, under treatment with neurohormonal antagonists for at least 3 months were retrospectively identified at a tertiary hospital's Heart Failure Clinic. Demographic, clinical, echocardiographic and treatment data were assessed. Patients were divided in three strata for each neurohormonal antagonist, according to the proposed framework: Status I – patients receiving target doses or the highest tolerated dose; Status II – use of subtarget doses for reasons unrelated to clinically important intolerance; and Status III – not receiving the drug at any dose. The prognostic value of each strata was assessed for all-cause mortality. Results A total of 408 patients (mean age 68±12 years, 78% male, 63% ischemic etiology) were included. The median LVEF was 31% (IQR 25–36) and most patients were in NYHA class II or III [210 (51.5%) and 163 (40%), respectively]. Medical therapy is described in Table 1. During a median follow-up of 3.3 years (IQR 1.4–5.6), 210 patients died. On univariable analysis, achieving Status I of beta-blocker (BB) therapy (HR: 0.50; 95% CI: 0.32–0.81; P=0.004) or ACEi/ARB (HR: 0.56; 95% CI: 0.36–0.86; P=0.012) was associated with reduced all-cause mortality. The mortality of patients in Status II of BB or ACEi/ARB was similar to the mortality of those not receiving the drug (HR for BB: 0.90; 95% CI: 0.53–1.52; P=0.69 and HR for ACEi/ARB: 0.71; 95% CI: 0.42–1.18; P=0.182) – figure 1. Achieving Status I of BB remained independently associated with reduced mortality after adjustment for several clinical and echocardiographic confounders (n=13) (adjusted HR: 0.59; 95% CI: 0.35–0.98; P=0.041). Conclusions In this real-world population of patients with HFrEF, the vast majority of patients were in Status I of BB and ACEi/ARB therapy. Achieving Status I of BB therapy seems to be associated with reduced mortality, even after adjustment for several markers of disease severity, highlighting the need for uptitration of medical therapy to maximal tolerated doses according to trial-proven regimens. Funding Acknowledgement Type of funding sources: None.</description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/eurheartj/ehab724.0914</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>European heart journal, 2021-10, Vol.42 (Supplement_1)</ispartof><rights>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Lopes, P</creatorcontrib><creatorcontrib>Albuquerque, F</creatorcontrib><creatorcontrib>Freitas, P</creatorcontrib><creatorcontrib>Presume, J</creatorcontrib><creatorcontrib>Rocha, B</creatorcontrib><creatorcontrib>Cunha, G</creatorcontrib><creatorcontrib>Strong, C</creatorcontrib><creatorcontrib>Tralhao, A</creatorcontrib><creatorcontrib>Trabulo, M</creatorcontrib><creatorcontrib>Ferreira, J</creatorcontrib><creatorcontrib>Ventosa, A</creatorcontrib><creatorcontrib>Aguiar, C</creatorcontrib><creatorcontrib>Mendes, M</creatorcontrib><creatorcontrib>Ferreira, A</creatorcontrib><title>Validation of a novel framework defining the acceptable standard of care for heart failure with reduced ejection fraction</title><title>European heart journal</title><description>Abstract Background In heart failure with reduced ejection fraction (HFrEF), uptitration of neurohormonal antagonists to trial-proven doses shown to reduce mortality is challenging and seldomly achieved in clinical practice. A major reason for underdosing of these agents is the lack of a clear description of what constitutes an acceptable standard of care in HFrEF. To address this limitation, a novel framework for describing the physician adherence to evidence-based treatment was recently proposed. The aim of our study was to evaluate and validate the proposed framework in a real-world population of patients with HFrEF. Methods A cohort of patients with HFrEF, defined as left ventricular ejection fraction (LVEF) &lt;40%, under treatment with neurohormonal antagonists for at least 3 months were retrospectively identified at a tertiary hospital's Heart Failure Clinic. Demographic, clinical, echocardiographic and treatment data were assessed. Patients were divided in three strata for each neurohormonal antagonist, according to the proposed framework: Status I – patients receiving target doses or the highest tolerated dose; Status II – use of subtarget doses for reasons unrelated to clinically important intolerance; and Status III – not receiving the drug at any dose. The prognostic value of each strata was assessed for all-cause mortality. Results A total of 408 patients (mean age 68±12 years, 78% male, 63% ischemic etiology) were included. The median LVEF was 31% (IQR 25–36) and most patients were in NYHA class II or III [210 (51.5%) and 163 (40%), respectively]. Medical therapy is described in Table 1. During a median follow-up of 3.3 years (IQR 1.4–5.6), 210 patients died. On univariable analysis, achieving Status I of beta-blocker (BB) therapy (HR: 0.50; 95% CI: 0.32–0.81; P=0.004) or ACEi/ARB (HR: 0.56; 95% CI: 0.36–0.86; P=0.012) was associated with reduced all-cause mortality. The mortality of patients in Status II of BB or ACEi/ARB was similar to the mortality of those not receiving the drug (HR for BB: 0.90; 95% CI: 0.53–1.52; P=0.69 and HR for ACEi/ARB: 0.71; 95% CI: 0.42–1.18; P=0.182) – figure 1. Achieving Status I of BB remained independently associated with reduced mortality after adjustment for several clinical and echocardiographic confounders (n=13) (adjusted HR: 0.59; 95% CI: 0.35–0.98; P=0.041). Conclusions In this real-world population of patients with HFrEF, the vast majority of patients were in Status I of BB and ACEi/ARB therapy. Achieving Status I of BB therapy seems to be associated with reduced mortality, even after adjustment for several markers of disease severity, highlighting the need for uptitration of medical therapy to maximal tolerated doses according to trial-proven regimens. Funding Acknowledgement Type of funding sources: None.</description><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqNkMtOwzAQRS0EEqXwC8g_kHbsOE68RBUvqRIbQOyiiT0mLmlSOQlV_562VKxZzdVI587oMHYrYCbApHMaY00Yh9WcaqxyqWZghDpjE5FJmRitsnM2AWGyROvi45Jd9f0KAAot9ITt3rEJDofQtbzzHHnbfVPDfcQ1bbv4xR350Ib2kw81cbSWNgNWDfF-wNZhdAfKYiTuu8iPf3CPoRn3m20Yah7JjZYcpxXZ45V99TFcswuPTU83pzllbw_3r4unZPny-Ly4WyZWpLlKMix8mkunlXciE1pJo7SRuULMwOu8qLxSqlIWQJOzrhAWpDDkdQoEKaRTpn97bez6PpIvNzGsMe5KAeVBYPknsDwJLA8C96D4Bbtx81_mB9QHeug</recordid><startdate>20211012</startdate><enddate>20211012</enddate><creator>Lopes, P</creator><creator>Albuquerque, F</creator><creator>Freitas, P</creator><creator>Presume, J</creator><creator>Rocha, B</creator><creator>Cunha, G</creator><creator>Strong, C</creator><creator>Tralhao, A</creator><creator>Trabulo, M</creator><creator>Ferreira, J</creator><creator>Ventosa, A</creator><creator>Aguiar, C</creator><creator>Mendes, M</creator><creator>Ferreira, A</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20211012</creationdate><title>Validation of a novel framework defining the acceptable standard of care for heart failure with reduced ejection fraction</title><author>Lopes, P ; Albuquerque, F ; Freitas, P ; Presume, J ; Rocha, B ; Cunha, G ; Strong, C ; Tralhao, A ; Trabulo, M ; Ferreira, J ; Ventosa, A ; Aguiar, C ; Mendes, M ; Ferreira, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1374-5a8f372d64fd1516429469274aa50f678bf444b4c006edcd81c0219ef630e0303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lopes, P</creatorcontrib><creatorcontrib>Albuquerque, F</creatorcontrib><creatorcontrib>Freitas, P</creatorcontrib><creatorcontrib>Presume, J</creatorcontrib><creatorcontrib>Rocha, B</creatorcontrib><creatorcontrib>Cunha, G</creatorcontrib><creatorcontrib>Strong, C</creatorcontrib><creatorcontrib>Tralhao, A</creatorcontrib><creatorcontrib>Trabulo, M</creatorcontrib><creatorcontrib>Ferreira, J</creatorcontrib><creatorcontrib>Ventosa, A</creatorcontrib><creatorcontrib>Aguiar, C</creatorcontrib><creatorcontrib>Mendes, M</creatorcontrib><creatorcontrib>Ferreira, A</creatorcontrib><collection>CrossRef</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lopes, P</au><au>Albuquerque, F</au><au>Freitas, P</au><au>Presume, J</au><au>Rocha, B</au><au>Cunha, G</au><au>Strong, C</au><au>Tralhao, A</au><au>Trabulo, M</au><au>Ferreira, J</au><au>Ventosa, A</au><au>Aguiar, C</au><au>Mendes, M</au><au>Ferreira, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Validation of a novel framework defining the acceptable standard of care for heart failure with reduced ejection fraction</atitle><jtitle>European heart journal</jtitle><date>2021-10-12</date><risdate>2021</risdate><volume>42</volume><issue>Supplement_1</issue><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract>Abstract Background In heart failure with reduced ejection fraction (HFrEF), uptitration of neurohormonal antagonists to trial-proven doses shown to reduce mortality is challenging and seldomly achieved in clinical practice. A major reason for underdosing of these agents is the lack of a clear description of what constitutes an acceptable standard of care in HFrEF. To address this limitation, a novel framework for describing the physician adherence to evidence-based treatment was recently proposed. The aim of our study was to evaluate and validate the proposed framework in a real-world population of patients with HFrEF. Methods A cohort of patients with HFrEF, defined as left ventricular ejection fraction (LVEF) &lt;40%, under treatment with neurohormonal antagonists for at least 3 months were retrospectively identified at a tertiary hospital's Heart Failure Clinic. Demographic, clinical, echocardiographic and treatment data were assessed. Patients were divided in three strata for each neurohormonal antagonist, according to the proposed framework: Status I – patients receiving target doses or the highest tolerated dose; Status II – use of subtarget doses for reasons unrelated to clinically important intolerance; and Status III – not receiving the drug at any dose. The prognostic value of each strata was assessed for all-cause mortality. Results A total of 408 patients (mean age 68±12 years, 78% male, 63% ischemic etiology) were included. The median LVEF was 31% (IQR 25–36) and most patients were in NYHA class II or III [210 (51.5%) and 163 (40%), respectively]. Medical therapy is described in Table 1. During a median follow-up of 3.3 years (IQR 1.4–5.6), 210 patients died. On univariable analysis, achieving Status I of beta-blocker (BB) therapy (HR: 0.50; 95% CI: 0.32–0.81; P=0.004) or ACEi/ARB (HR: 0.56; 95% CI: 0.36–0.86; P=0.012) was associated with reduced all-cause mortality. The mortality of patients in Status II of BB or ACEi/ARB was similar to the mortality of those not receiving the drug (HR for BB: 0.90; 95% CI: 0.53–1.52; P=0.69 and HR for ACEi/ARB: 0.71; 95% CI: 0.42–1.18; P=0.182) – figure 1. Achieving Status I of BB remained independently associated with reduced mortality after adjustment for several clinical and echocardiographic confounders (n=13) (adjusted HR: 0.59; 95% CI: 0.35–0.98; P=0.041). Conclusions In this real-world population of patients with HFrEF, the vast majority of patients were in Status I of BB and ACEi/ARB therapy. Achieving Status I of BB therapy seems to be associated with reduced mortality, even after adjustment for several markers of disease severity, highlighting the need for uptitration of medical therapy to maximal tolerated doses according to trial-proven regimens. Funding Acknowledgement Type of funding sources: None.</abstract><pub>Oxford University Press</pub><doi>10.1093/eurheartj/ehab724.0914</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0195-668X
ispartof European heart journal, 2021-10, Vol.42 (Supplement_1)
issn 0195-668X
1522-9645
language eng
recordid cdi_crossref_primary_10_1093_eurheartj_ehab724_0914
source Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title Validation of a novel framework defining the acceptable standard of care for heart failure with reduced ejection fraction
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T23%3A27%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Validation%20of%20a%20novel%20framework%20defining%20the%20acceptable%20standard%20of%20care%20for%20heart%20failure%20with%20reduced%20ejection%20fraction&rft.jtitle=European%20heart%20journal&rft.au=Lopes,%20P&rft.date=2021-10-12&rft.volume=42&rft.issue=Supplement_1&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/eurheartj/ehab724.0914&rft_dat=%3Coup_cross%3E10.1093/eurheartj/ehab724.0914%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/eurheartj/ehab724.0914&rfr_iscdi=true